Navigation Links
Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
Date:9/19/2013

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the BioCentury NewsMakers in the Biotech Industry conference at the Millennium Broadway Hotel in New York City on Friday, September 27, 2013.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, quizartinib, at 8:30 a.m. EDT.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available for 30 days following the initial presentation webcast. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.Ambit Contacts:Marcy Graham

Ian Stone/David SchullExecutive Director, Investor Relations & Corp Comm

Media ContactsAmbit Biosciences, Inc.

Russo Partners858-334-2125

619-308-6541/212-845-4271mgraham@ambitbio.com

ian.stone@russopartnersllc.com / david.schull@russopartnersllc.com


'/>"/>
SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
2. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
3. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
4. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. Natural Skin Care Solution, Probiotic Action Announces the Use of Their Probiotic Cleanser As a Anti-Acne Body Wash
9. Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients
10. Neogen announces 1st quarter results conference call
11. Global Industry Analysts, Inc. Announces the Launch of a Major Research Program Analysing the Global Market for Circulating Tumor Cells and Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... digital pathology and artificial intelligence Tuesday, July 25, during the Association of Pathology ... Johns Hopkins Medicine. , Baras, Associate Director of Pathology Informatics, will present ...
(Date:7/18/2017)... , ... July 18, 2017 , ... Sourcing custom glass ... your needs and has the capabilities to properly execute your job can take many ... is a sourcing portal designed to showcase the company’s capabilities and core ...
(Date:7/18/2017)... ... July 18, 2017 , ... Recently ... ( https://dataformsoftware.com ) announces the migration of its flagship cloud-based product Planet Life ... a team-centric, enterprise work management system that merges strategic and financial planning with ...
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental disorders ... range of overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) has ... research and testing. , However, designing a custom panel for disease research ...
Breaking Biology Technology:
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
Breaking Biology News(10 mins):